PD-L1 (Programmed death ligand 1)

P2, N=40, Withdrawn, Sydney Local Health District | Not yet recruiting --> Withdrawn

P2, N=278, Recruiting, AstraZeneca | Trial primary completion date: Mar 2027 --> Apr 2029

P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Dec 2029 | Trial primary completion date: Feb 2026 --> Dec 2029

Real-world evidence confirms the long-term effectiveness and safety of pembrolizumab monotherapy for advanced NSCLC with PD-L1 ≥50%. Survival outcomes closely mirrored those from previous trials, supporting the generalizability of pembrolizumab's benefit across routine practice.

P2, N=60, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Dec 2026 --> Feb 2025

P1/2, N=24, Not yet recruiting, University of Chicago

P3, N=336, Not yet recruiting, National Cancer Institute (NCI)

PACIFIC-R provides mature data on OS and rwPFS from a large, real-world cohort, supporting consolidation durvalumab as a standard of care in this setting.

Management required multidisciplinary coordination and included carboplatin, paclitaxel, and pembrolizumab, followed by radiation to the orbit, iliac crest, and mediastinal sites of disease. Unfortunately, he experienced progression while on maintenance immunotherapy with new rib and brain lesions, for which he underwent treatment with platinum, pemetrexed, and bevacizumab with additional radiotherapy...Our findings underscore the need for ophthalmology, radiation oncology, and medical oncology collaboration when vision-threatening or occult metastatic lesions arise., For readers, the takeaway is that choroidal metastasis-particularly in the era of immunotherapy-warrants individualized, multidisciplinary evaluation rather than default palliation. Our case demonstrates that coordinated multimodality management can achieve long-term disease control, highlighting a treatment paradigm worth considering for selected patients and calling for updated guidelines that reflect modern therapeutic capabilities.

Moreover, by light-irradiation-generating superoxide anions and hydroxyl radicals, P1-mediated photodynamic therapy achieves tumor-inhibiting action with approximately 92% regression in a breast mouse model and triggers immunogenic cell death induction, synergizing with programmed death-ligand 1 therapy to further activate systemic antitumor immunity and suppress both primary and distant tumors with approximately 95% tumor growth inhibition. Crucially, this platform may extend its applicability to diverse payloads such as imaging agents, therapeutics, and immunomodulators by replacing the PS warhead and advance delivery methods for clinical imaging and therapy.

In conclusions, FRA inhibited ESCC cell growth and immune evasion by inactivating HIF-1α/STAT3/PD-L1 signaling in vitro and vivo. This study suggested that FRA may serve as a potential therapeutic agent for ESCC treatment.

This is one of the first studies evaluating data on the expression of PDL-1 in oral cavity cancers in the Indian population and the factors affecting it. The data provides novel insights into many factors potentially affecting the expression of PDL-1 in oral cavity cancers and in the future, can be of help in developing treatment plans with various immunotherapies.